Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence

Journal of Hepatology

Volumn 61, Issue 3, 2014, Pages 492-501

  Inuzuka, Tadashi ^a   Ueda, Yoshihide ^a   Morimura, Hiroki ^a   Fujii, Yosuke ^a   Umeda, Makoto ^b   Kou, Tadayuki ^c   Osaki, Yukio ^d   Uemoto, Shinji ^a   Chiba, Tsutomu ^a   Marusawa, Hiroyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^c Kitano Hospital   (Japan)

^d OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

G1896A pre core variant; Genetic heterogeneity; Immunosuppressive therapy; Occult HBV infection; Ultra deep sequencing

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; ENTECAVIR; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB; STEROID; VIRUS DNA; HEPATITIS B CORE ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; COLON CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MIDDLE AGED; MUTATION RATE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; SEQUENCE ANALYSIS; SEROCONVERSION; TREATMENT WITHDRAWAL; VERY ELDERLY; VIRAL GENETICS; VIRUS CARRIER; VIRUS GENOME; VIRUS REACTIVATION; BLOOD; DRUG THERAPY; GENETICS; HETEROZYGOTE; PHYSIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; CARRIER STATE; DRUG THERAPY; FEMALE; GENETIC HETEROGENEITY; GENETIC VARIATION; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HETEROZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION;

EID: 84906315873     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.04.033     Document Type: Article

References (32)

1. J.R. Wands, C.M. Chura, F.J. Roll, and W.C. Maddrey Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders Gastroenterology 68 1975 105 112
2. R.M. Galbraith, A.L. Eddleston, R. Williams, and A.J. Zuckerman Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy Lancet 2 1975 528 530
3. J.H. Hoofnagle, G.M. Dusheiko, D.F. Schafer, E.A. Jones, K.C. Micetich, and R.C. Young et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy Ann Intern Med 96 1982 447 449
4. A.S. Lok, R.H. Liang, E.K. Chiu, K.L. Wong, T.K. Chan, and D. Todd Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 1991 182 188
5. I. Dervite, D. Hober, and P. Morel Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab N Engl J Med 344 2001 68 69
6. C.K. Hui, W.W. Cheung, H.Y. Zhang, W.Y. Au, Y.H. Yueng, and A.Y. Leung et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 2006 59 68
7. A.L. Mason, L. Xu, L. Guo, M. Kuhns, and R.P. Perrillo Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen Hepatology 27 1998 1736 1742
8. G. Raimondo, J.P. Allain, M.R. Brunetto, M.A. Buendia, D.S. Chen, and M. Colombo et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection J Hepatol 49 2008 652 657
9. S. Uemoto, K. Sugiyama, H. Marusawa, Y. Inomata, K. Asonuma, and H. Egawa et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants Transplantation 65 1998 494 499
10. H. Marusawa, S. Uemoto, M. Hijikata, Y. Ueda, K. Tanaka, and K. Shimotohno et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen Hepatology 31 2000 488 495
11. H. Marusawa, S. Imoto, Y. Ueda, and T. Chiba Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen J Gastroenterol 36 2001 633 636
12. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
13. S. Kusumoto, Y. Tanaka, M. Mizokami, and R. Ueda Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma Int J Hematol 90 2009 13 23
14. C. Rodriguez, S. Chevaliez, P. Bensadoun, and J.M. Pawlotsky Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing Hepatology 58 2013 890 901
15. N. Nishijima, H. Marusawa, Y. Ueda, K. Takahashi, A. Nasu, and Y. Osaki et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing PLoS One 7 2012 e35052
16. M. Omata, T. Ehata, O. Yokosuka, K. Hosoda, and M. Ohto Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis N Engl J Med 324 1991 1699 1704
17. W.F. Carman, E.A. Fagan, S. Hadziyannis, P. Karayiannis, N.C. Tassopoulos, and R. Williams et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis Hepatology 14 1991 219 222
18. A. Ozasa, Y. Tanaka, E. Orito, M. Sugiyama, J.H. Kang, and S. Hige et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection Hepatology 44 2006 326 334
19. J.L. Steinberg, W. Yeo, S. Zhong, J.Y. Chan, J.S. Tam, and P.K. Chan et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role J Med Virol 60 2000 249 255
20. T. Umemura, E. Tanaka, K. Kiyosawa, and H. Kumada Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan Clin Infect Dis 47 2008 e52 e56
21. H. Marusawa, Y. Osaki, T. Kimura, K. Ito, Y. Yamashita, and T. Eguchi et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan Gut 45 1999 284 288
22. E. Cholongitas, G.V. Papatheodoridis, and A.K. Burroughs Liver grafts from anti-hepatitis B core positive donors: a systematic review J Hepatol 52 2010 272 279
23. S. Chevaliez, C. Rodriguez, and J.M. Pawlotsky New virologic tools for management of chronic hepatitis B and C Gastroenterology 142 2012 e1301
24. J. Polson, and W.M. Lee AASLD position paper: the management of acute liver failure Hepatology 41 2005 1179 1197
25. S. Sato, K. Suzuki, Y. Akahane, K. Akamatsu, K. Akiyama, and K. Yunomura et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis Ann Intern Med 122 1995 241 248
26. T. Matsumoto, H. Marusawa, M. Dogaki, Y. Suginoshita, and T. Inokuma Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection Liver Int 30 2010 1241 1242
27. C. Hsu, H.H. Tsou, S.J. Lin, M.C. Wang, M. Yao, and W.L. Hwang et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study Hepatology 59 2014 2092 2100
28. T. Pollicino, G. Raffa, L. Costantino, A. Lisa, C. Campello, and G. Squadrito et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma Hepatology 45 2007 277 285
29. P.P. Scaglioni, M. Melegari, and J.R. Wands Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame Virology 233 1997 374 381
30. S.J. Hadziyannis, and D. Vassilopoulos Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 2001 617 624
31. D.R. Milich, M.K. Chen, J.L. Hughes, and J.E. Jones The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence J Immunol 160 1998 2013 2021
32. C.J. Chu, and A.S. Lok Clinical significance of hepatitis B virus genotypes Hepatology 35 2002 1274 1276